This article was originally published in The Gray Sheet
Executive SummaryCholestech GDX system will be distributed globally by Abbott to physician offices and hospital-based customers under an agreement signed July 24. GDX, which measures glycated hemoglobin rates, provides an average glucose level from the previous 90 days and offers an immediate risk assessment of diabetes. For the first quarter ended June 28, Cholestech sales were off 6% to $11.6 mil., while earnings rose 13% to $1.4 mil...
You may also be interested in...
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with three new products including Novartis's Beovu for treating neovascular (wet) age related macular degeneration. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).